Published in AIDS Weekly, October 5th, 1998
These data, presented at a late-breaker slide session at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held in San Diego, California, September 1998, suggest that the drug is well-positioned for front-line combination antiretroviral therapy that includes a protease inhibitor, says its corporate developer, Vertex.
Interim 16 week...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.